Association of quality of life and disease control with cigarette smoking in patients with severe asthma

V.C.H. dos Santos1 00, M.A.F. Moreira2 00, A.V. da Rosa3 00, S.M. Sobragi3 00, C.A.J. da Silva3 00, and P.T.R. Dalcin4 00

1Programa de Pós-Graduação em Ciências Pneumológicas, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Fundacão Hospitalar Getúlio Vargas, Sapucaia do Sul, RS, Brasil
2Servicio de Pneumología, Hospital das Clínicas de Porto Alegre, Porto Alegre, RS, Brasil
3Curso de Graduação, Faculdade de Fisioterapia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil
4Programa de Pós-Graduação em Ciências Pneumológicas, Departamento de Medicina Interna, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Servicio de Pneumología, Hospital das Clínicas de Porto Alegre, Porto Alegre, RS, Brasil

Abstract

More information is needed on asthma control and health-related quality of life (HRQoL) in smokers with severe asthma. The main study objective was to characterize the association of HRQoL and disease control with cigarette smoking in individuals with severe asthma. A secondary objective was to analyze subject characteristics according to asthma onset: asthma that developed before smoking initiation versus asthma that developed after smoking initiation. This cross-sectional study included subjects with severe asthma aged 18–65 years. HRQoL was assessed using the Asthma Quality of Life Questionnaire (AQLQ) and asthma control was assessed using the Asthma Control Test (ACT) and Global Initiative for Asthma (GINA) criteria. Of the 87 patients studied, 58 (66.7%) were classified as asthmatics who had never smoked and 29 (33.3%) as asthmatics with smoking exposure. The proportion of subjects with uncontrolled asthma was higher in the asthma and smoking group (GINA criteria: P=0.032 and ACT criteria: P=0.003. There were no between-group differences in overall AQLQ score (P=0.475) or AQLQ domain scores (P>0.05). Fifty-eight subjects (66.7%) were nonsmokers, 20 (23%) had asthma onset before smoking, and 9 (10.3%) had asthma onset after smoking. Asthma onset before smoking was associated with uncontrolled asthma (P=0.013). In subjects with severe asthma, smoking was associated with a higher rate of uncontrolled disease but not with HRQoL scores.

Key words: Adult; Asthma quality of life questionnaire; Cross-sectional study; Cigarette

Introduction

The aim of asthma treatment is to achieve disease control or maintain the current level of control and prevent future risks (exacerbations, instability of the disease, accelerated loss of lung function, and adverse effects of treatment) (1). Asthma control treatment is divided into steps 1 to 5, in which the dose of inhaled corticosteroids is progressively increased or other controller medications are added. Steps 4 and 5 represent more severe disease (2).

Severe asthma is asthma that is uncontrolled despite adherence to optimized high doses of inhaled corticosteroid/long-acting beta-agonist therapy and treatment of contributory factors. Currently, asthma severity is assessed retrospectively in terms of the level of treatment required to control symptoms and exacerbations. Asthma severity is assessed after the patient has been on controller treatment for several months and, if appropriate, treatment step-down has been attempted to determine the patient’s minimum level of treatment (1,2). Although patients with severe asthma account for only 5–10% of asthma cases (2), they have higher morbimortality and account for a disproportionate use of healthcare resources compared with less severe groups (3).

Although smoking has declined considerably over the last 20 years in developed countries (4), cigarette smoking is still surprisingly common in asthma patients. The association between cigarette smoking and asthma can be harmful (5). In a Brazilian study (6), 7.8% of asthmatics were exposed to cigarette smoking. Smoking is associated with worse levels of asthma control, more symptomatology, more frequent exacerbations, and higher mortality (7,8). Asthmatic smokers have more severe asthma symptoms, greater need for rescue
medication, and worse health status indicators than individuals who have never smoked (9–11). Smoking is associated with greater lung function decline, increased health care costs, and lower therapeutic response to inhaled corticosteroids (12–14). Even ex-smoker asthmatics have higher asthma symptom scores and lower lung function than never smokers (5,15). Exposure to household air pollution and smoking is common in adults with asthma in Salvador, Brazil. Additionally, this dual exposure is associated with worse spirometric parameters, worse disease control, and greater asthma severity, indicating the harmful effect of this exposure (6).

It has been suggested that only asthma subjects with few symptoms and/or preserved lung function continue to smoke, and that subjects with more severe asthma refrain from smoking. This “healthier smoker” effect may explain the lack of association between cigarette smoke and asthma symptoms and the risk of developing asthma found in some studies (5).

Although smoking is known to worsen asthma control, there are few clinical studies on the association between severe asthma and smoking. There is a need for more information about asthma control and health-related quality of life (HRQoL) among adult smokers with severe asthma receiving tertiary care in southern Brazil.

Therefore, this study aimed to characterize the association of HRQoL and disease control with cigarette smoking in individuals with severe asthma. A secondary aim was to analyze patient characteristics according to asthma onset: asthma that developed before smoking initiation versus asthma that developed after smoking initiation.

**Material and Methods**

This was a cross-sectional study approved by the Ethics and Research committee of the Hospital de Clínicas de Porto Alegre (HCPA), number 1.139.117. All study methods were carried out in accordance with international and national guidelines and regulations for clinical studies of humans (Declaration of Helsinki and Brazilian Governmental regulation – Plataforma Brasil). All patients signed an informed consent form.

Patients were recruited from the Asthma Outpatient Clinic of HCPA, Brazil. All patients who volunteered were sequentially included. The study included asthmatic patients aged between 18 and 65 years. The diagnosis was confirmed by compatible history of asthma and evidence of reversible airflow obstruction. This evidence was confirmed by spirometry showing airflow limitation, characterized by forced expiratory volume in the first second (FEV1) less than 80% of the predicted value and FEV1/forced vital capacity (FVC) ratio less than 75%; substantial improvement in airflow after inhalation of short-acting beta2-agonist bronchodilator (BD) (increase in FEV1 greater than 12% in relation to the pre-BD value and greater than 200 mL in absolute value); or increase in FEV1 greater than 20% and exceeding 250 mL spontaneously over time or after intervention with medication. All patients included in the study were being treated according to step 4 or 5 of the Global Initiative for Asthma (GINA) (16).

Asthmatic subjects exposed to smoking were included. Individuals who reported smoking in the past 30 days and had a smoking index higher than 5 pack-years were considered active smokers. Smokers in the cessation phase or ex-smokers were defined as individuals who had quit smoking during the last 30 days or more and had a smoking index greater than 5 pack-years. A control group of asthmatic nonsmokers included individuals who reported never having smoked and ex-smokers with a smoking index of less than 5 pack-years.

The following were excluded from the study: pregnant women, patients with other chronic lung diseases such as bronchiectasis, sequelae of pulmonary tuberculosis, diffuse lung fibrosis, lung neoplasm or neoplasm of other sites, human immunodeficiency syndrome, acquired immunodeficiency syndrome, or congenital immunodeficiency syndrome, psychiatric illness or incapacitating chronic neurological disease that could prevent the performance of the study procedures, and patients who did not complete the study evaluation tests.

The smoking index (pack-years) was calculated as follows: (number of cigarettes smoked per day/20) × the number of years the person had smoked.

Asthmatic patients were classified according to the temporal association between smoking initiation and asthma onset: asthma onset before smoking initiation, asthma onset after smoking initiation, and nonsmoking asthmatics.

HRQoL was assessed using Juniper’s Asthma Quality of Life Questionnaire (AQLQ) (17,18). The AQLQ comprises four domains: symptoms, activity limitation, emotional function, and environmental exposure. Each domain is scored from 1 to 7; the score of 1 indicates maximal impairment and the score of 7 indicates no impairment.

The level of asthma control was assessed using the Asthma Control Test (ACT) (19) and the GINA table (16). The Charlson Comorbidity Index (20) was also used.

Spirometry was performed using a Jaeger v 4.31a spirometer (Jaeger, Germany). The following variables were recorded: FVC in liters and percentage of predicted value, FEV1 in liters and percentage of predicted value, and FEV1/FVC ratio in absolute value and percentage of predicted value. The carbon monoxide diffusing capacity (DLCO) was measured by a single sustained breath of a special gaseous mixture, using Master Screen Diffusion equipment (Jaeger). Pulmonary volumes were measured using the Master Screen Body-Plets (Jaeger). Lung function variables in nomograms were reported as a percentage of predicted values for gender, age, and height (21–23).
The six-minute walk test (6MWT) was performed according to the guidelines of the American Thoracic Society (24). Total distance walked in 6 min was recorded, and baseline and post-test peripheral oxygen saturation were measured using a pulse oximeter (NPB-40; Nellcor Puritan Bennett, USA).

A sample of the population underwent induced sputum examination to evaluate cellularity (25,26). We considered the sputum sample as eosinophilic if the percentage of eosinophils was \( \geq 3\% \) (27).

A blood count analysis was performed, and a total eosinophil count of 351 eosinophils/microliter or more was considered eosinophilia (26). The serum immunoglobulin E (IgE) dose was analyzed and considered high if greater than 100 IU/mL, according to the reference value (28).

The skin prick test for allergy was conducted according to published protocols (29).

**Statistical analysis**

All data were processed and analyzed using the Statistical Package for the Social Sciences, version 22.0 (SPSS Inc., USA). Quantitative variables are reported as means ± SD or median and interquartile range. Categorical variables are reported using absolute and relative frequencies.

Pearson’s chi-square test or Fisher’s exact test were used to test for associations between categorical variables. To compare means, we used Student’s t-test or one-way analysis of variance, supplemented by Tukey’s test. In case of asymmetry, Mann-Whitney or Kruskal-Wallis test was used and supplemented by the Dunn’s test.

A P-value \( \leq 0.05 \) was considered statistically significant and all tests were two-tailed.

**Results**

From October 2015 to June 2017, we assessed 494 adult subjects. Of these, 87 patients were included and completed the study (see Figure 1). Table 1 shows the overall characteristics of the study sample. Of all subjects, 58 (66.7%) were never smokers, 22 (25.3%) were former smokers, and only 7 (8%) were current smokers.

![Figure 1. Flow diagram of study selection.](image-url)
Comparison between asthmatics with and without smoking exposure

The mean age was higher for asthmatics with smoking exposure (55.8 ± 8.5 years) than for the never smokers group (42.4 ± 13.3 years, P < 0.001). The median Charlson score was higher in the asthma-smoking group (3 points) than in the asthma-never smoker group (1 point, P < 0.001) (Table 1).

Table 2 compares HRQoL scores (AQLQ), asthma control, IgE levels, blood and sputum eosinophil counts, and skin prick test results between groups. There were no significant between-group differences for overall AQLQ score (P=0.475) or for AQLQ domain scores (symptoms, P=0.331; activity limitation, P=0.347; emotional function, P=0.589; environmental stimulus, P=0.449). The proportion of subjects with uncontrolled asthma was higher in the asthma-smoking group than in the asthma-never smoker group both for GINA criteria (respectively, 51.7 vs 48.3%; P=0.032) and ACT criteria ≤20 (respectively, 93.1 vs 63.8; P=0.003). The proportion of positive skin tests for allergies was lower in the asthma-smoking group than in the asthma-never smoker group (respectively, 34.5 vs 67.2%, P=0.007).

Table 3 compares pulmonary function and 6MWT results. At the time of diagnosis, mean values of pre-BD and post-BD FEV1 (% of predicted value) were lower for the asthma-smoking group (respectively, 58.5 ± 16.7% and 71.8 ± 16.6% of predicted value) than for the asthma-never smoker group (respectively, 69.9 ± 18.1% and 82.5 ± 18.6%; P=0.006 and P=0.011). At study inclusion, mean values of pre-BD FVC, post-BD FEV1, pre-BD FEV1/FVC, and DLco were significantly lower for the asthma-smoking group than in the asthma-never smoker group for both GINA criteria (respectively, 51.7 vs 48.3%; P=0.032) and ACT criteria ≤20 (respectively, 93.1 vs 63.8; P=0.003). The proportion of positive skin tests for allergies was lower in the asthma-smoking group than in the asthma-never smoker group (respectively, 34.5 vs 67.2%, P=0.007).
## Table 2. Comparison of quality of life, asthma control, IgE, eosinophils, and skin test between groups.

| Variables                               | Asthma with smoking exposure (n=29) | Asthma and never smokers (n=58) | P  |
|-----------------------------------------|-------------------------------------|---------------------------------|----|
| AQOLQ, means ± SD                       | 4.39 ± 1.27                         | 4.60 ± 1.32                     | 0.475 |
| AQOLQ Symptoms                          | 4.65 ± 1.20                         | 4.94 ± 1.36                     | 0.331 |
| AQOLQ Activity Limitation               | 4.36 ± 1.45                         | 4.66 ± 1.35                     | 0.347 |
| AQOLQ Emotional Function                | 4.59 ± 2.18                         | 4.34 ± 1.92                     | 0.589 |
| AQOLQ Environmental Stimulus            | 3.43 ± 1.78                         | 3.75 ± 1.87                     | 0.449 |
| Asthma control (GINA), n (%)            | 0.032                               |                                 |    |
| Controlled/partly controlled            | 8 (27.6)                            | 21 (72.4)                       |    |
| Uncontrolled                            | 30 (51.7)                           | 28 (48.3)                       |    |
| Asthma control test, points - median (IR) | 14 (12–16)                          | 17 (11.8–21)                    | 0.036 |
| Asthma control test (< 20 points; uncontrolled), n (%) | 27 (93.1)                           | 37 (63.8)                       | 0.003 |
| Serum IgE (IU/mL); median (IR)         | 74 (32–349)                         | 154 (46–464)                    | 0.169 |
| IgE classification, n (%)               | 0.255                               |                                 |    |
| Normal (> 100)                          | 17 (58.6)                           | 25 (43.1)                       |    |
| High (> 100)                            | 12 (41.4)                           | 33 (56.9)                       |    |
| Serum eosinophils (eosinophils/μL), means ± SD | 0.29 (0.20–0.59)                    | 0.24 (0.12–0.59)                | 0.400 |
| Sputum eosinophils, n (%)               | 0.241                               |                                 |    |
| Unsuitable sample (saliva), n (%)       | 6 (25.0)                            | 21 (43.8)                       |    |
| <3%                                     | 13 (54.2)                           | 17 (35.4)                       |    |
| >3%                                     | 5 (20.8)                            | 10 (20.8)                       |    |
| Skin test, n (%)                        | 0.007                               |                                 |    |
| Positive                                | 10 (34.5)                           | 39 (67.2)                       |    |
| Negative                                | 19 (65.5)                           | 19 (32.8)                       |    |

n: number of cases; AQOLQ: Asthma Quality of Life Questionnaire; GINA: Global Initiative for Asthma; IgE: immunoglobulin E; IR: interquartile range (25th–75th percentiles). Pearson’s chi-square test or Fisher’s exact test for categorical variables; t-test for independent samples or Mann-Whitney test for continuous variables.

## Table 3. Pulmonary function and 6-minute walk test.

| Variables                               | Asthma with smoking exposure (n=29) | Asthma and never smokers (n=58) | P  |
|-----------------------------------------|-------------------------------------|---------------------------------|----|
| Pulmonary function, mean ± SD          |                                    |                                 |    |
| At diagnosis                            |                                     |                                 |    |
| Pre-BD FVC (% predicted)                | 74.5 ± 16.8                         | 85.2 ± 18.4                     | 0.011 |
| Pre-BD FEV₁ (% predicted)               | 58.5 ± 16.7                         | 69.9 ± 18.1                     | 0.006 |
| Pre-BD FEV₁/FVC (%)                     | 62.8 ± 11.3                         | 66.5 ± 12.7                     | 0.193 |
| Post-BD FVC (% predicted)               | 88.0 ± 14.2                         | 94.5 ± 19.8                     | 0.124 |
| Post-BD FEV₁ (% predicted)              | 71.8 ± 16.6                         | 82.5 ± 18.6                     | 0.011 |
| Post-BD FEV₁/FVC (%)                    | 66.9 ± 13.7                         | 74.4 ± 12.3                     | 0.012 |
| At inclusion in the study               |                                     |                                 |    |
| Pre-BD FVC (% predicted)                | 73.6 ± 16.1                         | 83.5 ± 16.0                     | 0.008 |
| Pre-BD FEV₁ (% predicted)               | 59.5 ± 18.7                         | 73.5 ± 18.2                     | 0.001 |
| Pre-BD FEV₁/FVC (%)                     | 65.4 ± 11.7                         | 72.5 ± 9.4                      | 0.003 |
| Post-BD FVC (% predicted)               | 80.1 ± 14.2                         | 86.5 ± 16.9                     | 0.080 |
| Post-BD FEV₁ (% predicted)              | 67.0 ± 17.8                         | 79.3 ± 18.2                     | 0.004 |
| Post-BD FEV₁/FVC (%)                    | 69.4 ± 13.2                         | 78.4 ± 11.5                     | 0.002 |
| DLC0cSB (%)                             | 67.9 ± 22.6                         | 80.3 ± 15.5                     | 0.013 |
| TLC (%)                                 | 112.4 ± 13.4                        | 108.9 ± 20.1                    | 0.406 |
| FRC (%)                                 | 136.7 ± 32.2                        | 121.7 ± 27.6                    | 0.027 |
| RV (%)                                  | 177.8 ± 50.5                        | 165.2 ± 47.1                    | 0.252 |
| Distance walked in 6-MWT (m), mean ± SD | 436.3 ± 75.7                        | 459.4 ± 74.6                    | 0.181 |

n: number of cases; BD: short-acting β₂-agonist bronchodilator; FVC: forced vital capacity; FEV₁: forced expiratory volume in the first second; DLC0cSB: diffusing capacity for carbon monoxide adjusted for hemoglobin; TLC: total lung capacity; FRC: functional residual capacity; RV: residual volume; 6MWT: 6-min walk test. t-test for independent samples or Mann-Whitney test.
group (respectively, 73.6 ± 16.1, 59.5 ± 18.7, 65.4 ± 11.7, and 67.9 ± 22.6% of predicted value) than for the asthmanever smoker group (respectively, 83.5 ± 16.0, P=0.008; 73.5 ± 18.2, P=0.001; 72.5 ± 9.4, P=0.003; and 80.3 ± 15.5, P=0.013). The asthma-smoking group had significantly higher functional residual capacity values (136.7 ± 32.2% of predicted value) than the asthmanever smoker group (121.7 ± 27.6% of predicted value; P=0.027).

Comparison of asthma onset among groups

Table 4 compares the “asthma onset before smoking,” “asthma onset after smoking,” and “nonsmoking asthmatic” groups. There were 58 (66.7%) subjects in the nonsmoking group, 20 subjects (23%) in the group with asthma onset before smoking, and 9 subjects (10.3%) in the group with asthma onset after smoking. The nonsmoking asthmatic group was younger than the other two groups. There were 58 (66.7%) subjects in the nonsmoking group, 20 subjects (23%) in the group with asthma onset before smoking, and 9 subjects (10.3%) in the group with asthma onset after smoking. The nonsmoking asthmatic group was younger than the other two groups.

Table 4. Characteristics of patients according to the onset of asthma: asthma developed before starting cigarette smoking versus asthma developed after initiating cigarette smoking.

| Variables                        | Asthma onset before smoking | Asthma onset after smoking | Nonsmoking asthmatics | P       |
|----------------------------------|-----------------------------|---------------------------|-----------------------|---------|
|                                  | (n=20)                      | (n=9)                     | (n=58)                |         |
| Age (years), mean ± SD           | 54.6 ± 9.5*                 | 58.6 ± 5.1*               | 42.4 ± 13.3*          | <0.001  |
| Gender, n (%)                    |                             |                           |                       | 0.017   |
| Male                             | 8 (40.0)*                   | 0 (0.0)                   | 9 (15.5)              |         |
| Female                           | 12 (60.0)*                  | 9 (100)                   | 49 (84.5)             |         |
| Age at diagnosis of asthma (years), median (IR) | 6.5 (2.3–35.3)             | 44 (23.5–49.5)            | 11.5 (2–30)           | 0.770   |
| BMI (kg/m²), mean ± SD           | 31.7 ± 4.5                  | 30.2 ± 8.3                | 30.7 ± 8.8            | 0.789   |
| Charlson Comorbidity Index, median (IR) | 3 (2–3)                   | 3 (2–4)                   | 1 (1–2)               | <0.001  |
| Asthma control (GINA), n (%)     |                             |                           |                       | 0.048   |
| Controlled/partially controlled   | 4 (20.0)*                   | 4 (44.4)                  | 30 (51.7)*            |         |
| Uncontrolled                     | 16 (80.0)*                  | 5 (55.6)                  | 28 (48.3)*            |         |
| Asthma control test, points-median (IR) | 14 (12–17.5)               | 14 (11.5–15)              | 17 (11.8–21)          | 0.110   |
| Asthma control test, < 20 points (well controlled), n (%) | 19 (95.0)*                  | 8 (88.9)                  | 37 (63.8)*            | 0.013   |
| Quality of life, mean ± SD       |                             |                           |                       |         |
| AQLQ                             | 4.62 ± 1.03                 | 3.88 ± 1.64               | 4.60 ± 1.32           | 0.285   |
| AQLQ Symptoms                    | 4.80 ± 0.95                 | 4.33 ± 1.66               | 4.94 ± 1.36           | 0.426   |
| AQLQ Activity Limitation         | 4.67 ± 1.11                 | 3.67 ± 1.92               | 4.66 ± 1.35           | 0.128   |
| AQLQ Emotional Function          | 4.97 ± 2.26                 | 3.73 ± 1.82               | 4.34 ± 1.92           | 0.267   |
| AQLQ Environmental Stimulus      | 3.51 ± 1.73                 | 3.25 ± 1.99               | 3.75 ± 1.87           | 0.706   |
| Pulmonary function, mean ± SD    |                             |                           |                       |         |
| Pre-BD FVC (% predicted)         | 74.2 ± 16.9a                | 72.4 ± 14.9ab             | 83.5 ± 16.0b          | 0.030   |
| Pre-BD FEV₁ (% predicted)        | 60.1 ± 19.0a                | 58.1 ± 19.2ab             | 73.5 ± 18.2b          | 0.005   |
| Pre-BD FEV₁/FVC (%)              | 65.9 ± 12.4a                | 64.1 ± 10.6ab             | 72.5 ± 9.4c           | 0.011   |
| Post-BD FVC (% predicted)        | 82.0 ± 15.0                 | 75.8 ± 11.7               | 86.5 ± 16.9           | 0.136   |
| Post-BD FEV₁ (% predicted)       | 69.4 ± 18.4ab               | 61.7 ± 16.3*              | 79.3 ± 18.2c          | 0.009   |
| Post-BD FEV₁/FVC (%)             | 70.4 ± 12.5a                | 67.2 ± 15.2*              | 78.4 ± 11.5c          | 0.005   |
| DLCCo SB (% predicted)           | 69.9 ± 23.5ab               | 63.6 ± 21.1*              | 80.3 ± 15.5c          | 0.012   |
| TLC (% predicted)                | 112.2 ± 11.6                | 113.0 ± 17.6              | 108.9 ± 20.1          | 0.705   |
| FRC (%)                          | 136.0 ± 32.2                | 138.3 ± 34.3              | 121.7 ± 27.6          | 0.085   |
| RV (% predicted)                 | 182.3 ± 51.2                | 167.8 ± 50.4              | 165.2 ± 47.1          | 0.394   |
| Distance walked in 6MWT (m), mean ± SD | 448.3 ± 64.3               | 409.7 ± 44.8              | 459.4 ± 74.6          | 0.180   |
| Eosinophilia (cells/μL), mean ± SD | 252 ± 186                   | 267 ± 270                 | 331 ± 306             | 0.506   |
| Sputum eosinophils, n (%)        |                             |                           |                       | 0.458   |
| Unsuitable sample (sputa), n (%) | 5 (27.8)                    | 10 (55.6)                 | 3 (16.7)              |         |
| <3%                              | 1 (16.7)                    | 3 (50)                    | 2 (33.3)              |         |
| >3%                              | 21 (43.8)                   | 17 (35.4)                 | 10 (20.8)             |         |
| IgE (IU/mL), median (IR)         | 117 (65.7–441.7)            | 56 (34.1–171.1)           | 192 (79.8–490)        | 0.139   |

n: number of cases; BMI: body mass index; GINA: Global Initiative for Asthma; ACT: Asthma Control Test; AQLQ: Asthma Quality of Life Questionnaire; BD: short-acting β₂-agonist bronchodilator; FVC: forced vital capacity; FEV₁: forced expiratory volume in the first second; TLC: total lung capacity; FRC: functional residual capacity; RV: residual volume; 6MWT: 6-min walk test; IgE: immunoglobulin E; IR: interquartile range (25th–75th percentiles). Pearson’s chi-square test or Fisher’s exact test for categorical variables; *adjusted residual >1.96 or <−1.96 (implies significantly different percentages). Analysis of variance for continuous variables and Tukey post hoc test or Kruskal-Wallis tests and Dunn’s post hoc test: different letters indicate significantly different means.
groups (respectively, 42.4 ± 13.3, 58.6 ± 5.1, 54.6 ± 9.5; P < 0.001). The median Charlson comorbidity indexes were significantly higher in the groups with asthma onset before smoking and asthma onset after smoking than in the nonsmoking asthmatic group (P < 0.001). The proportion of subjects with uncontrolled asthma was higher in the group with asthma onset before smoking (80% GINA classification, P=0.048; 95% for ACT score, P=0.013). Pre-BD values of FVC, FEV₁, FEV₁/FVC, and DLco were higher for the group with asthma onset before smoking.

**Post hoc analysis**

We performed a comparison between never smokers, current smokers, and former smokers. There was a significant age difference at study inclusion (41.6 ± 18.9 years, 45.0 ± 11.4 years, and 56.9 ± 7.5 years, respectively; P < 0.0001). There was also a significant difference in ACT scores (17.1 ± 5.6, 11.5 ± 3.7, and 15.4 ± 4.2, respectively; P=0.039) and no differences in gender, lung function at study inclusion, and HRQoL scores.

**Discussion**

In this cross-sectional study of patients with severe asthma treated at a large, university-affiliated tertiary care hospital in southern Brazil, we observed a higher rate of uncontrolled asthma in asthmatics who smoked than in non-smoker asthmatics in terms of both GINA criteria and ACT criteria. There were no significant between-group differences in overall AQLQ scores or AQLQ domain scores. Additionally, 66.7% of subjects were classified as non-smokers, 23% as having asthma onset before smoking, and 10.3% as having asthma onset after smoking. The proportion of subjects with uncontrolled asthma was higher in the group with asthma onset before smoking. There was no association between group and AQLQ scores.

It is worth noting that in our sample, only 7 (8%) subjects were current smokers. This low proportion of current smokers can be explained by the intensive educational efforts toward smoking cessation in the severe asthma outpatient clinic. This finding may also partly reflect the healthier smoker effect, in which only individuals with few asthma symptoms and/or preserved lung function continue to smoke, and subjects with more severe asthma refrain from smoking (5). Because of this limitation, data for current and former smokers were combined for analysis to form the group with asthma associated with smoking.

Althuis et al. (10) examined the association between cigarette smoking and asthma symptom severity in 225 asthmatic patients aged 20–54 years. Similar to our findings, they showed that cigarette smoking was associated with a higher frequency of asthma symptoms. However, in adjusted multivariate analyses, the relationship between smoking and higher overall asthma symptoms was of borderline significance (P=0.06).

Siroux et al. (11) analyzed 200 adult asthmatic subjects, 265 non-asthmatic controls, and 586 relatives of asthmatics (147 with asthma). The inclusion criteria classified asthmatics as mild, moderate, or severe. They concluded that active smoking is not a risk factor for asthma in adulthood, but that smoking increases asthma severity. Current smokers compared with never and ex-smokers had more asthma symptoms, more frequent asthma attacks, and higher asthma severity scores.

Dalcin et al. (30) investigated asthma control in 275 patients aged 11 years or older. In contrast to the present findings, there was no association with smoking status, but the study included patients with a wide age range and different severity classification (52.4% were classified as severely asthmatic, 33.8% as moderate, and 17.5% as mild).

Our finding that the groups with asthma associated with smoking and with asthma not associated with smoking did not differ on AQLQ overall or domain scores was unexpected. There are several explanations for this finding. First, patients with more severe forms of asthma may have worse HRQoL, regardless of smoking status (31). Second, this finding may reflect, at least partly, the healthy smoker effect (5). Third, the sample size may have been too small for the magnitude of the differences in AQLQ scores.

HRQoL was an important outcome, because the effect of asthma on activities of daily life is very important for patients, although it remains unclear which tool is the most suitable for assessing HRQoL. There are eleven instruments for adults that measure the impact effect of asthma on quality of life, but none is qualified as core instruments because they predominantly measure indicators of asthma control (symptoms and/or functional status), fail to provide a distinct, reliable score for measuring all key dimensions of the intended construct, and/or lack adequate psychometric data (32).

Boulet et al. (33) studied corticosteroid-naive asthma patients (no treatment for asthma used except for short-acting beta₂-agonists on demand) and compared the clinical features of 22 smoking asthma patients and 27 non-smoking asthma patients. Similar to our own findings, the mean HRQoL global score was similar in smokers and nonsmokers. There were no differences in symptoms, activities, emotions, or environment. In contrast to the present findings, other studies (11,31,34) have demonstrated substantial associations between smoking and HRQoL in asthma subjects. However, most of the patients in these studies had mild or moderate asthma.

In the present study, the proportion of positive skin tests for allergies was significantly lower in the group with asthma associated with smoking. Skin tests are used in addition to a directed history and physical exam to exclude or confirm IgE-mediated diseases such as allergic rhinitis and asthma and anaphylaxis to Aeroallergens, foods, insect venoms, and certain drugs.
Many chronic conditions and their treatments affect the response to asthma treatments or increase the difficulty of achieving asthma control. It has been demonstrated that comorbidities can adversely affect the long-term course of severe asthma (35). In this study, we found that non-smoker asthmatics had lower Charlson comorbidity scores than smokers.

Compared with subjects with asthma not associated with smoking, asthma associated with smoking had lower mean expiratory flow and lung diffusion capacity, and higher functional residual capacity. Several other studies have found worse lung function values in asthmatic smokers (13,14,33,36,37). Most subjects in our group with asthma associated with smoking met the criteria for asthma-chronic obstructive pulmonary disease syndrome (38).

There is a lack of studies that sufficiently characterize possible asthma phenotypes associated with asthma onset: asthma that developed before smoking initiation versus asthma that developed after smoking initiation. In this study, 23% of subjects had asthma onset before smoking and only 10.3% had asthma onset after smoking. The proportion of uncontrolled asthma was higher in subjects who had asthma onset before smoking. Lung function was worse in those who had asthma onset before smoking. Raherison et al. (36) examined asthma phenotypes according to the timing of smoking onset in young adults. Forty-six subjects (48%) were nonsmokers and 50 (52%) were current or former smokers; 39 had had their first asthma attack before starting smoking, and 11 had started smoking before having their first asthma attack. Asthma that developed before smoking initiation and asthma without smoking were both strongly related to nasal allergy, parental asthma, and atopy. Only a lower FEV₁ level was substantially associated with asthma after smoking initiation. It is possible that, at least in some subjects, smoking requires an additional comorbid condition to influence asthma development or clinical expression (39).

The present study has some potential limitations. First, this was a cross-sectional study, so it was not possible to establish a temporal link between smoking in asthma subjects and quality of life. Second, the study was conducted in a single center and the sample was small. Third, there was an age difference between the groups with asthma associated with smoking and asthma not associated with smoking. This difference may reflect differences in phenotypes and in disease and severity progression. The effect of asthma on HRQoL is likely to differ according to several patient factors, including age. Fourth, in the current study we did not perform a direct correlation or association analysis between quality of life and asthma control for smoking history.

In conclusion, this cross-sectional study of patients with severe asthma identified a higher rate of uncontrolled asthma in subjects with asthma associated with smoking than in those with asthma not associated with smoking. However, there were no between-group differences in HRQoL scores. In addition, 66.7% of subjects were classified as nonsmoking, 23% as having asthma onset before smoking, and only 10.3% as having asthma onset after smoking. For better clarification of the association of HRQoL and disease control with cigarette smoking in severe asthma, further longitudinal studies with a large sample size are needed.

Acknowledgments

This research was supported by Fundo de Pesquisa do Hospital de Clínicas de Porto Alegre (FIP-E-HCPA, protocol number 1.139.117). A.V. da Rosa and S.M. Sobragi received scholarships from Conselho Nacional de Desenvolvimento Científico e Tecnológico (PIBIC/ CNPq). C.A.J. da Silva received an extension grant from Pró-Reitoria de Extensão, UFRGS.

References

1. Pizzichini MMM, de Carvalho-Pinto RM, Cançado JED, Rubin AS, Neto AC, Cardoso AP, et al. 2020 Brazilian Thoracic Association recommendations for the management of asthma. J Bras Pneumol 2020; 46: e20190307, doi: 10.1590/1806-3713/e20190307.
2. GINA (Global Initiative for Asthma). Global strategy for asthma management and prevention (2021 update). 2021. p 1–215. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Accessed March 16, 2021.
3. Serra-Battles J, Plaza V, Morejón E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 1322–1326, doi: 10.1183/09031936.98.12061322.
4. WHO (World Health Organization). WHO/Europe | Tobacco - Data and statistics. Data and Statistics 2021. Geneva: World Health Organization; 2021.
5. Cerveri I, Cazzoletti L, Corsico AG, Marcon A, Niniano R, Grosso A, et al. The impact of cigarette smoking on asthma: a population-based international cohort study. Int Arch Allergy Immunol 2012; 158: 175–183, doi: 10.1159/000330900.
6. Fernandes AGO, de Souza-Machado C, Pinheiro GP, de Oliva ST, Mota RCL, De Lima VB, et al. Dual exposure to smoking and household air pollution is associated with an increased risk of severe asthma in adults in Brazil. Clin Transl Allergy 2018; 8: 48, doi: 10.1186/s13601-018-0235-6.
Cigarette smoking and severe asthma

7. Mcleish AC, Zvolensky MJ. Asthma and cigarette smoking: a review of the empirical literature. J Asthma 2010; 47: 345–361, doi: 10.3109/0277090903556413.

8. Harmsen L, Gottlieb V, Makowska Rasmussen L, Backer V. Asthma in smoke-free children who smoke have signs of chronic airflow limitation before age 45. J Asthma 2010; 47: 362–366, doi: 10.3109/02770909103692819.

9. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24: 822–833, doi: 10.1183/09031936.04.0039004.

10. Althuis MD, Sexton M, Prybylski D. Cigarette smoking and severe asthma: a review of the empirical literature. J Asthma 2010; 47: 362–366, doi: 10.3109/02770909103692819.

11. Siroux V, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Asthma and cigarette smoking: a review of the empirical literature. J Asthma 2010; 47: 362–366, doi: 10.3109/02770909103692819.

12. Thomson NC, Shepherd M, Spears M, Chaudhuri R. Corticosteroid insensitivity in smokers with asthma: clinical evidence, mechanisms, and management. Treat Respir Med 2006; 5: 467–481, doi: 10.2165/00151829-200605060-00010.

13. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226–230, doi: 10.1136/thorax.57.3.226.

14. Kim SY, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Asthma and cigarette smoking: a review of the empirical literature. J Asthma 2010; 47: 362–366, doi: 10.3109/02770909103692819.

15. Thomson NC, Shepherd M, Spears M, Chaudhuri R. Corticosteroid insensitivity in smokers with asthma: clinical evidence, mechanisms, and management. Treat Respir Med 2006; 5: 467–481, doi: 10.2165/00151829-200605060-00010.

16. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226–230, doi: 10.1136/thorax.57.3.226.

17. Kim SY, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Asthma and cigarette smoking: a review of the empirical literature. J Asthma 2010; 47: 362–366, doi: 10.3109/02770909103692819.

18. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226–230, doi: 10.1136/thorax.57.3.226.

19. Kim SY, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Asthma and cigarette smoking: a review of the empirical literature. J Asthma 2010; 47: 362–366, doi: 10.3109/02770909103692819.

20. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226–230, doi: 10.1136/thorax.57.3.226.

21. Kim SY, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Asthma and cigarette smoking: a review of the empirical literature. J Asthma 2010; 47: 362–366, doi: 10.3109/02770909103692819.

22. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226–230, doi: 10.1136/thorax.57.3.226.

23. Kim SY, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Asthma and cigarette smoking: a review of the empirical literature. J Asthma 2010; 47: 362–366, doi: 10.3109/02770909103692819.

24. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226–230, doi: 10.1136/thorax.57.3.226.
36. Raherison C, Baldi I, Tunon-De-Lara JM, Taytard A, Annesi-Maesano I. Asthma phenotypes according to the timing of smoking onset in young adults. *Int J Tuberc Lung Dis* 2003; 7: 84–92.

37. Tomlinson JEMM, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. *Thorax* 2005; 60: 282–287, doi: 10.1136/thx.2004.033688.

38. Postma DS, Rabe KF. The asthma-COPD overlap syndrome. *N Engl J Med* 2015; 373: 1241–1249, doi: 10.1056/NEJMra1411863.

39. Boulet LP. Influence of comorbid conditions on asthma. *Eur Respir J* 2009; 33: 897–906, doi: 10.1183/09031936.00121308.